IDF2022-0414 iGlarLixi Provides a Higher Derived Time-in-Range vs Insulin Glargine or Lixisenatide in Asian Pacific People with T2D

Autor: X. Guo, W. Yang, J. Zhang, X. Dong, M. Liu, S. u, F. Lauand, L. Li, E. Souhami

Publikováno v: Diabetes Research and Clinical Practice. 197:110307

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c8cf9c390ffc42e72d11ce9b71dea4a
https://doi.org/10.1016/j.diabres.2023.110307

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of morphometric assessment of prevalent vertebral deformities in women using different reference data

Autor: Pierre D. Delmas, Françoise Munoz, Jose R. Zanchetta, S Young, Elisabeth Sornay-Rendu, E Paris, A Bagur, M.J van der Mooren, E Souhami, Pawel Szulc

Publikováno v: Szulc, P, Munoz, F, Sornay-Rendu, E, Souhami, E, Zanchetta, J R, Bugur, A, van der Mooren, M J, Young, S & Delmas, P D 2000, ' Comparison of morphmometric assessment of prevalent vertebral deformities in women using different reference data. ', Bone, vol. 27, no. 6, pp. 841-6 . https://doi.org/10.1016/S8756-3282(00)00398-7
Bone, 27(6), 841-6. Elsevier Inc.

The semiquantitative assessment of vertebral deformities is based on visual evaluation. The quantitative approach is based on different morphometric criteria. This study is aimed at comparing the impact of different reference groups to define normal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79c25747ede3650e9f0d9c92419f9ca4
https://doi.org/10.1016/s8756-3282(00)00398-7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of insulin glulisine in patients with type 1 diabetes

Autor: M. Dreyer, K. Busch, R. Van Leendert, R. Prager, G. Ellis, E. Souhami, A. Robinson

Publikováno v: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 37(11)

Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. The aim of this multinational, multi-centre, controlled,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b08d6c4ab9594342a0df00b0ad5ec3
https://pubmed.ncbi.nlm.nih.gov/16308840